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Ischemia/reperfusionathway for bulk turnover of long-lived proteins and organelles via lysosomal
degradation. Growing evidence reveals that autophagy is involved in the progression or prevention of many
human diseases. Here we discuss the role of autophagy in the normal heart, in heart disease and
atherosclerosis. In the heart, autophagy functions predominantly as a pro-survival pathway during cellular
stress by removing protein aggregates and damaged organelles, protecting the heart against famine,
excessive β-adrenergic stimulation and ischemia. However, when severely triggered, e.g. during reperfusion,
the autophagic machinery may lead to cell death. Furthermore, autophagy modulates cardiac hypertrophy
and the transition from hypertrophy to heart failure. During aging, lipofuscin is formed via autophagy in the
heart and impairs autophagy. Basal autophagy in atherosclerotic plaques is a survival mechanism
safeguarding plaque cells against cellular distress, in particular oxidative injury, metabolic stress and
inﬂammation, by removing harmful oxidatively modiﬁed proteins and damaged components. Hence,
autophagy is anti-apoptotic and contributes to cellular recovery in an adverse environment. However,
excessively stimulated autophagy causes autophagic death in plaque cells and is detrimental. Ceroid that is
formed via autophagy in atherosclerotic arteries impairs autophagy and induces apoptosis. Basal autophagy
can be intensiﬁed by appropriate drugs and pharmacological approaches have been developed to stabilize
rupture-prone plaques through selective induction of macrophage autophagic death, without affecting the
plaque stabilizing smooth muscle cells.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionMacroautophagy (further referred to as autophagy) is a dynamic
and highly regulated process of self-digestion. The hallmark of
autophagy is the de novo formation of autophagosomes, which are
double-membrane vacuoles originating from a largely undeﬁned
structure, known as the phagophore or isolation membrane. The
process shows elongation of the isolation membrane, maturation of
the autophagosome followed by its fusion with a lysosome, thereby
generating an autophagolysosome or autolysosome. The incorpora-
tion of the outer autophagosomal membrane with the lysosomal
membrane eventually allows the degradation of the remaining inner
single-membrane and the cytoplasmic content of the autophagosome
by lysosomal hydrolases. Autophagy is a highly conserved cellular
process responsible for the removal or recycling of long-lived proteins
and organelles, which also provides cells with an alternate source of
nutrients from the reutilization of cellular proteins and organelles.
This lysosomal degradation pathway is essential for survival, differ-
entiation, development, and homeostasis. In eukaryotic cells, autop-
hagy occurs constitutively at low levels to perform housekeeping
functions such as the destruction of dysfunctional organelles.32 3 820 25 67.
eyer).
ll rights reserved.Upregulation occurs in the presence of external stressors (e.g.
starvation, hormonal imbalance, oxidative stress) and internal needs
(e.g. removal of protein aggregates), suggesting that the process is an
important survival mechanism. Indeed, autophagy principally serves
an adaptive role to protect organisms against diverse pathologies [1],
including heart disease [2]. However, in certain circumstances, the
self-cannibalistic function of autophagy may be deleterious [3].
Several lines of evidence indicate that autophagy is associated with
heart disease, cancer and a number of neurodegenerative disorders
such as Alzheimer's, Parkinson's and Huntington's disease. In addition,
autophagy plays a role in development, aging and immunity [4–6].
2. Autophagy in the normal heart and in heart disease
One of the ﬁrst reports that described autophagy in the heart was
published in the mid 1970s, one decade after the initial description of
autophagy in mammalian cells [7]. Sybers et al. [8] observed that fetal
mouse heart in culture continues to beat for a period of weeks, but
that degenerative changes occur. Electron microscopy revealed
formation of autophagic vacuoles containing damaged organelles in
some cells after the ﬁrst day, indicating focal cytoplasmic injury. This
process was accelerated by transient deprivation of oxygen or glucose.
At present, several lines of evidence indicate that autophagy is indeed
essential for cellular homeostasis in the heart, maintaining cardiac
structure and function [9,10]. Autophagy under baseline conditions
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defect in this pathway will result in adverse effects for the heart. For
instance, severe cardiac dysfunction occurs in patients and mice
showing defective autophagic degradation owing to a deﬁciency of
the lysosomal-associated membrane protein-2 (LAMP-2) [11,12]. This
disorder, also known as Danon's disease [13,14], is a lysosomal
glycogen storage disease characterized by cardiomyopathy, myopathy
and variable mental retardation. Mutations in the coding sequence of
LAMP-2 cause a LAMP-2 deﬁciency and extensive autophagy in
skeletal and heart muscle.
While autophagy is an ongoing process in baseline conditions, it is
more apparent in disease. Increased autophagic activity in cardio-
myocytes has been described after multiple forms of cardiovascular
stress, including starvation, chronic ischemia, infarction–reperfusion
injury, pressure overload, cardiomyopathy, and heart failure [15–20].
Whether autophagy functions as a pro-survival or pro-death program
during disease is still not completely understood [21]. Autophagy can
have both beneﬁcial and detrimental roles in the myocardium,
depending on the level of autophagy. Upregulation of autophagy
may be beneﬁcial to the cell by recycling of proteins to generate free
amino acids and fatty acids needed to maintain energy production, by
removing damaged organelles, and by preventing accumulation of
protein aggregates. However, enhanced autophagy can also contribute
to cell death, possibly through excessive self-digestion. Numerous
autophagosomes are often seen in dying cells, but it is not clear
whether autophagy directly contributes to cell death or is upregulated
as an effort to prevent it.
2.1. Autophagy removes protein aggregates in the heart
Cardiomyocytes face enormous challenges to correctly fold nascent
polypeptides and to keepmature proteins from denaturing. They have
developed multi-layered protein quality control mechanisms which
are carried out primarily by chaperones and ubiquitin–proteasome
system (UPS)-mediated proteolysis. Autophagy also participates in
protein quality control in cardiomyocytes, especially under patholo-
gical conditions. The UPS is responsible for the degradation of short-
lived proteins, such as cytosolic, nuclear, and myoﬁbrillar proteins,
whereas autophagy regulates levels of long-lived proteins and
organelles [9]. The UPS and autophagy are generally considered to
be two separate degradation pathways, but recent ﬁndings have
demonstrated that there may be cross-talk between the two path-
ways. Cardiac protein quality control often becomes inadequate in
heart disease, whichmay play an important role in the development of
congestive heart failure [22]. Cardiomyocytes with deﬁcient autop-
hagy have increased levels of ubiquitinated proteins in autophago-
somes, indicating that autophagymaywork in parallel with the UPS to
turnover cellular proteins [9]. Moreover, cardiac-speciﬁc deﬁciency of
Atg5 leads to cardiac hypertrophy, left ventricular dilatation and
contractile dysfunction in adult mice [14]. Atg5-deﬁcient hearts show
increased levels of ubiquitination, disorganized sarcomeres and
mitochondrial aggregation [14]. However, embryonic Atg5 knockout
mice are viable and live to adulthood without any detectable heart
abnormalities [14], presumably due to compensatory mechanisms
which also perform cellularmaintenance. Given that the production of
polyubiquitinated proteins is often increased during cardiomyopathy
and chronic heart failure [22], it is likely that autophagy provides
protection by degrading misfolded proteins and aberrant protein
aggregates that may be toxic to cardiomyocytes. Indeed, pressure
overload promotes accumulation of polyubiquitinated protein aggre-
gates in the left ventricle, development of aggresome-like structures,
and a corresponding induction of autophagy [23]. This ﬁnding situates
pressure-overload heart disease in the category of proteinopathy.
Moreover, attenuation of autophagic activity enhances aggresome size
and abundance, which is consistent with a role for autophagic activity
in protein aggregate clearance in the heart.Aberrant protein aggregation in the form of pre-amyloid oligomers
(PAOs) has been observed in failing mouse and human hearts [24].
Indeed, cardiomyocyte expression of a polyglutamine (PQ) PAO causes
heart failure [25,26]. Intracellular PAOs cause toxicity in many of the
protein misfolding-based neurodegenerative diseases. For example, in
Huntington's disease, long (N50) PQ repeats form PAOs and cause
neurotoxicity, whereas shorter PQ peptides are benign. In transgenic
mice, hearts expressing an 83 residue-long PQ repeat (PQ83) show
reduced cardiac function and dilation by 5 months, and mice die by 8
months. In contrast, control mice, expressing non-amyloid-forming
peptideof 19 PQ repeats, have normal cardiac function,morphology, and
life span. PQ83 protein accumulates within aggresomes with PAO-
speciﬁc staining. ThePQ83heartsexhibit increasedautophagosomal and
lysosomal content but also show markers of necrotic death, including
inﬂammatory cell inﬁltration and increased sarcolemmal permeability.
Thus, protein misfolding resulting in intracellular PAO accumulation is
sufﬁcient to cause cardiomyocyte death and heart failure.
Furthermore, a severe form of desmin-related cardiomyopathy is
also characterized by accumulation of misfolded proteins [24]. This
disease is triggered by a missense mutation in the alphaB-crystallin
(CryAB) gene. Mutant CryAB (CryAB(R120G)) induces an increase in
cardiomyocyte autophagic activity [27]. Blunting autophagy increases
the rate of aggregate accumulation and the abundance of insoluble
CryAB(R120G)-associated aggregates. Cardiomyocyte-restricted over-
expression of CryAB(R120G) in mice induces intracellular aggregate
accumulation and systolic heart failure by twelve months. Well before
the earliest decline in cardiac function, signiﬁcant autophagic activity
is present. Blunting autophagy in vivo, through crossbreeding CryAB
(R120G) mice with animals harboring heterozygous inactivation of
beclin 1, a protein required for early autophagosome formation,
accelerates heart failure progression with an increase in interstitial
ﬁbrosis, greater accumulation of polyubiquitinated proteins, larger
and more extensive intracellular aggregates, accelerated ventricular
dysfunction, and early mortality. Thus, autophagy is also activated in
desmin-related cardiomyopathy and is an adaptive response to
protein aggregates in this proteotoxic form of heart disease [27].
2.2. Autophagy removes damaged organelles in the heart
Besides removal of toxic protein aggregates, autophagy can also
provide protection to the heart by removing damaged and dysfunc-
tional organelles. In particular, the removal of leaky mitochondria
releasing pro-apoptotic factors such as cytochrome c [28] and
apoptosis inducing factor [29] may protect cells by preventing
activation of apoptosis. Many studies have described mitochondria
sequestered inside autophagosomes in the myocardium after cellular
distress [8,29,30]. Sybers et al. [8] noted numerous autophagosomes
containingmitochondria in fetal hearts in organ culture after hypoxia/
reoxygenation. Decker and Wildenthal [30] also observed that many
autophagic vacuoles contained damaged mitochondria during reper-
fusion and proposed that autophagy is upregulated to remove
damaged mitochondria. Since the mitochondrial permeability transi-
tion pore opens when reperfusion is initiated after ischemia [31], it
might serve as a signal to autophagosomes to sequester the
mitochondria. Furthermore, the mitochondrial protein Bnip3 (Bcl-2/
adenovirus E1B 19 kDa interacting protein) is upregulated in
cardiomyocytes subjected to ischemia and stimulates apoptotic cell
death signaling during ischemia/reperfusion (I/R) injury of the heart
via disruption of mitochondrial integrity, which in turn leads to
enhanced superoxide production and the release of pro-apoptotic
factors. Bnip3 activation is associated with upregulation of autophagy
as determined by high levels of autophagosomes containing frag-
mented mitochondria. Upregulation of autophagy most likely con-
stitutes a protective response against Bnip3 death signaling by
removing harmful and leaky mitochondria, thus preventing activation
of apoptosis (Fig. 1) [29].
Fig. 1. Induction of autophagy in the heart after ischemia/reperfusion. During ischemia,
oxygen and nutrient supplies are decreased, causing activation of AMP-activated protein
kinase (AMPK) and inactivation of mammalian target of rapamycin (mTOR), which in
turn leads to autophagy for cell survival. Furthermore, Bcl-2/adenovirus E1B 19 kDa
interacting protein (Bnip3) is involved in upregulation of autophagy and functions as a
cytoprotective pathway to oppose ischemia/reperfusion-related apoptosis. Upon
reperfusion, activation of AMPK and inactivation of mTOR are no longer observed.
Instead, expression of beclin 1 is markedly upregulated. The ability of beclin 1 to
promote autophagy is negatively regulated by interaction with Bcl-2. The latter protein
is degraded by the ubiquitin–proteasome system, which is activated during oxidative
stress. The combination of upregulation of beclin 1 and downregulation of Bcl-2 during
the reperfusion phase stimulates the activity of beclin 1, thereby stimulating autophagic
cell death. Thus it seems that autophagy in patients should be stimulated in the middle
of ischemia but must be inhibited during reperfusion.
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detrimental during reperfusion
Autophagy may promote survival by maintaining energy home-
ostasis during ischemia. Although induction of autophagy during the
ischemic phase is protective, further enhancement of autophagy
during the reperfusion phase may induce cell death and appears to be
detrimental [32], as explained below.
2.3.1. Autophagy during ischemia
Langendorff perfused rabbit hearts subjected to I/R show signs of
autophagy induction [30,33]. Twenty minutes of ischemia does not
induce autophagy, but the number of autophagosomes increases
when reperfusion is initiated. However, 40 min of ischemia alone
causes an increase in autophagy which is further enhanced during
reperfusion. When ischemia is extended to 60 min, large and likely
dysfunctional lysosomes are present during reperfusion, suggesting
that prolonged ischemia impairs the autophagic-lysosomal pathway.
Under ischemia, oxygen and nutrient supplies are decreased and the
intracellular generation of ATP via oxidative phosphorylation is
reduced. These stimuli induce autophagy [34], which may be
protective. Indeed, degradation of proteins and organelles by
autophagy generates free amino acids and fatty acids, which can be
used to maintain mitochondrial ATP production and protein synthesis
and promote survival of cardiac cells. Thus, the increase in autophagy
correlates with functional recovery and salvage of the myocardium
after I/R, whereas extended ischemia correlates with irreversible
damage and contractile dysfunction [30]. Both mammalian targets of
rapamycin (mTOR) dependent and independent pathways regulate
the initiation and maturation of autophagy [35]. mTOR is a serine/
threonine kinase and a member of the PI kinase-related family that
controls the response to changes in nutrients. Ischemia induces
cardiac autophagy on condition that AMP-activated protein kinase
(AMPK) is activated [32,36]. AMPK activation probably triggers
induction of autophagy through inhibition of mTOR [32,37] (Fig. 1),
followed by phosphorylation of eukaryotic elongation factor-2 and
inhibition of protein synthesis [37,38].2.3.2. Autophagy during reperfusion
During the reperfusion phase, activation of AMPK is no longer
observed, but expression of beclin 1 is markedly upregulated [32,36]
(Fig. 1). AMPK is rapidly inactivated upon reperfusion, but over-
expression of beclin 1 in cardiac myocytes following I/R enhances
formation and downstream lysosomal degradation of autophago-
somes (autophagic ﬂux) and signiﬁcantly reduces activation of the
pro-apoptotic protein Bax [39]. Moreover, autophagosome formation
during reperfusion is signiﬁcantly inhibited in beclin 1+/− mice [36].
The mechanism that drives upregulation of beclin 1 in the heart is
presently unknown. Recent evidence suggests that nitric oxide (NO) is
not involved in increased beclin 1 expression, though NO plays a
crucial role in the process of I/R and heart failure by regulating several
members of the caspase family [40]. In vascular smooth muscle cells
(SMCs), tumor necrosis factor-α (TNFα) induces upregulation of
beclin 1 expression and subsequent autophagy through the JNK
pathway [41]. Since JNK is activated by reperfusion [42], beclin 1 may
be upregulated by JNK during the reperfusion phase. Simultaneously,
increased oxidative stress and ER stress may occur, which may further
stimulate autophagy [32] (Fig. 1).
In contrast to the generally protective effects of autophagy
during ischemia, autophagy during the reperfusion phase may not
necessarily be protective. For instance, inhibition of hypoxia and
reoxygenation-induced autophagy leads to enhanced cardiac myo-
cyte survival in vitro [43]. Moreover, inhibition of autophagy during
the reperfusion phase is accompanied by signiﬁcant reduction in
the size of myocardial infarction and cardiac myocyte apoptosis in
beclin 1+/− mice [36]. Several factors could render autophagy
detrimental in the heart during reperfusion. First, excessive
activation of autophagy could cause cell death. Second, the
combination of upregulation of beclin 1 and downregulation of
Bcl-2 during the reperfusion phase would stimulate the activity of
beclin 1, thereby stimulating cell death. The ability of beclin 1 to
promote autophagy is negatively regulated by interaction with Bcl-
2 [44] (Fig. 1). The latter protein is degraded by the UPS, which is
activated during oxidative stress [45]. Third, autophagy and
apoptosis are interconnected by common mediators. E.g. Atg5
interacts with Fas-associated death domain (FADD) protein, an
adaptor molecule involved in mediating receptor-mediated apop-
tosis, and mediates interferon-γ (IFN-γ) induced cell death[46].
Moreover, upregulation of calpain during I/R may convert initial
activation of autophagy by Atg5 to apoptosis [47]. Indeed, cleavage
of Atg5 by calpain promotes the translocation of truncated Atg5 to
the mitochondria where it interacts with Bcl-XL and triggers
permeabilization of the outer mitochondrial membrane [47]. Over-
expression of truncated Atg5 induces apoptosis but is unable to
promote autophagy. Fourth, selective degradation of catalase may
play a role as well [32].
Thus it seems that autophagy in patients should be stimulated in
the middle of ischemia but must be inhibited during reperfusion.
However, whether induction of autophagy during I/R is beneﬁcial or
detrimental may also depend on the extent of the initial ischemia. If
the level of ischemia is modest, activation of autophagy at reperfusion
may also be modest and thus protective. Interestingly, myocardial
protection elicited by adaptation to ischemia is mediated in associa-
tionwith BAG-1 protein (Bcl-2-associated athanogene) [48]. The latter
is a multifunctional pro-survival molecule that binds with Hsp70/
Hsc70 and enhances the anti-apoptotic effects of Bcl-2. Moreover,
hibernation, a reversible arrest of contractile function, is an important
energy-saving adaptation to chronic hypoxia that enables cardiomyo-
cytes to withstand severe ischemic insults. Autophagy seems to be a
key pro-survival mechanism in hibernating cardiomyocytes [49],
which represent the critical reserve of dysfunctional cells that can be
potentially rescued. Certainly, more investigations are needed to
translate our knowledge regarding autophagy to clinical treatment in
order to reduce I/R injury.
Fig. 2. Dual role of autophagy in the heart and in atherosclerosis. During nutrient deprivation and cellular stress, autophagy functions predominantly as a pro-survival pathway in the
heart. However, when severely triggered the autophagic machinery may be used for self-destruction, ﬁnally leading to heart failure. During ischemia low levels of autophagy protect
against cell death byproviding the cell with free fatty acids and amino acids and by removing damaged organelles, whereas during reperfusion high levels or long-termupregulation of
autophagy trigger cell death. In atherosclerosis, mild oxidative stress activates autophagy to facilitate the removal of damaged organelles. Successful autophagy of the damaged
components contributes to cellular recovery. If autophagy is not sufﬁcient for the removal of the cellular damage, e.g. in the case of severe oxidative stress, leakage of
intramitochondrial components such as cytochrome cmay induce apoptosis through activation of the caspase cascade. Moreover, oxidative damage of the lysosomal membrane often
results in cytosolic leakage of potent hydrolases,which could cause substantial cytosolic damage followedbyapoptosis. Severe oxidative stress combinedwith autophagymayalso lead
to formation of ceroid, a complex of protein associated with oxidized lipids. Ceroid deposits cannot be degraded by lysosomal hydrolases and might lead to preferential allocation of
lysosomal enzymes to ceroid-loaded lysosomes at the expense of active autolysosomeswhich in turnwould lead to progressive inhibition of autophagy and the induction of apoptosis.
Autophagic cell death of smoothmuscle cells (SMC) of the ﬁbrous cap may lead to plaque destabilization and autophagic cell death of endothelial cells (EC) may result in thrombosis.
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hypertrophy to heart failure
In the setting of hemodynamic stress, such as occurs in hyperten-
sion or following myocardial infarction, the heart undergoes a
compensatory hypertrophic growth response. Left unchecked, this
hypertrophic response triggers myocyte death, ventricular dilation,
diminished contractile performance, and a clinical syndrome of heart
failure. For some years, autophagy has been implicated in the
pathophysiology of heart failure [50]. For example, in isolated
neonatal myocytes, inhibition of autophagy by knockdown of Atg7
using RNAi induces hypertrophy, and conditional deletion of Atg5 in
the heart results in increased cross-sectional area of the myocytes
[14]. On the other hand, the mTOR inhibitor rapamycin, a potent
activator of autophagy, prevents cardiac hypertrophy induced by
thyroid hormone treatment [51] or aortic banding [52]. Rapamycin
treatment can even regress already established cardiac hypertrophy
induced by pressure overload and improves cardiac function [53].
Thus, autophagy might antagonize cardiac hypertrophy by increasing
protein degradation which would decrease cardiac mass.
In contrast, increased autophagy in hypertrophied hearts may
also play a role in the transition from stable cardiac hypertrophy to
decompensated heart failure [54]. Pressure overload induced by
aortic banding evokes heart failure and greatly increases cardiac
autophagy. Load-induced autophagic activity peaks at 48 h and
remains signiﬁcantly elevated for at least 3 weeks. In addition,
autophagic activity is not spatially homogeneous but rather is seen
at particularly high levels in basal septum. Heterozygous disruption
of the gene coding for beclin 1 decreases cardiomyocyte autophagy
and diminishes pathological remodeling induced by severe pressure
stress. Conversely, beclin 1 overexpression increases autophagic
activity and accentuates pathological remodeling (hypertrophy
upon pressure overload). Taken together, these ﬁndings implicateautophagy in the pathogenesis of load-induced heart failure and
suggest that it may be a target for novel therapeutic intervention
[54]. Furthermore, the level of autophagy in the heart is an
important factor in determining whether autophagy will be
protective or detrimental. By giving intramuscular injections of
diphtheria toxin, Akazawa et al. [55] observed degeneration of
cardiomyocytes within 7 days in transgenic mice that express
human diphtheria toxin receptor in the heart. Approximately 80% of
the animals showed pathophysiological features characteristic of
heart failure and were dead within 14 days. Degenerated
cardiomyocytes of the transgenic heart showed several character-
istics indicative of autophagic cell death such as upregulation of
lysomal markers and accumulation of autophagosomes. Moreover,
the high levels of autophagy observed in the failing heart support
the theory that excessive induction of autophagy underlies
autophagic cell death and loss of cardiomyocytes (Fig. 2). Indeed,
dead and dying cardiomyocytes showing characteristics of autop-
hagy have been reported in heart failure caused by dilated
cardiomyopathy [15,16,56], valvular and hypertensive heart disease
[57], chronic ischemia [17], and stunned or hibernating myocardium
[18,58], but not in normal heart [16,18]. The incidence of autophagic
cardiomyocytes in failing hearts is greater than the incidence of
apoptotic cells (0.03–0.3% versus ≤0.002%, based on stainings for
granular ubiquitin inclusions or TUNEL, respectively [15,16,18]).
Therefore, autophagy is suggested to be an important mechanism
underlying the cardiomyocyte dropout responsible for the worsen-
ing of heart failure [59]. However, it remains unclear whether
autophagy is a sign of failed cardiomyocyte repair or a suicide
pathway for the failing cardiomyocytes [60].
Autophagy in cardiomyocytes is not conﬁned to heart failure, but
also occurs in patients suffering from a cardiomyopathy without
overt heart failure. For example, Saijo et al. [19] reported a case of
cardiomyopathy in which most of the myocytes were affected by
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lack of diastolic dysfunction. Autophagic cell death was accompa-
nied by a markedly elevated (600 μg/ml) plasma level of brain
natriuretic peptide that might have caused induction of autophagy
in the heart. Apart from cardiomyocytes, autophagy also occurs in
interstitial cells of the aortic valve of patients with severe aortic
valve stenosis [61].
2.5. Autophagy protects against famine and excessive β-adrenergic
stimulation of the heart
Autophagy serves as a catabolic energy source in times of famine.
Cardiac myocytes from starved mice display high numbers of
autophagosomes to survive the adverse conditions of nutrient
deprivation [62]. Autophagy in cardiac myocytes has also been
suggested to provide a necessary source of energy between birth and
suckling [63].
β-adrenergic stimulation, which promotes apoptosis [64] and
induces cardiac hypertrophy and heart failure [65], has been reported
to inhibit autophagy [66]. Cardiac myocytes isolated from Atg5
deﬁcient mouse heart have increased sensitivity to the β-adrenocep-
tor agonist isoproterenol compared to wild type cells [14]. Moreover,
isoproterenol treatment for 7 days leads to left ventricular dilation and
cardiac dysfunction in autophagy deﬁcient mice but not in wild type
mice, suggesting that autophagy protects cells against excessive β-
adrenergic stimulation.
2.6. Lipofuscin is formed via autophagy in the heart and impairs
autophagy during aging
Lipofuscin is a nondegradable, yellow-brown pigment composed
of lipid and protein residues that progressively accumulates in cardiac
myocytes and other long-lived postmitotic cells. Autophagy in the
heart is responsible for the formation of lipofuscin [67]. Hydrogen
peroxide (H2O2) generated by mitochondria and other organelles
permeates in the lumen of secondary lysosomes [67]. These lysosomes
contain iron derived from cellular structures undergoing autophagic
degradation. The interaction between reactive ferrous iron and H2O2
results, via fenton reactions, in the generation of hydroxyl radicals
inducing lipid peroxidation and eventually intermolecular cross-
linking and lipofuscin formation [67]. Although autophagy is a
nonstop renewal process responsible for the degradation of damaged
organelles and macromolecules, degenerative changes gradually
advance in the aging heart, even under favorable conditions [68].
This ﬁnding suggests that autophagy is unable to completely remove
all damaged structures. Progressive inhibition of autophagy in the
aging heart is at least in part attributed to intralysosomal accumula-
tion of lipofuscin. Cross-linked polymeric lipofuscin cannot be
degraded by lysosomal hydrolases and might lead to preferential
allocation of lysosomal enzymes to lipofuscin-loaded lysosomes at the
expense of active autolysosomes [68]. Impaired autophagy stimulates
further accumulation of damaged mitochondria, increased reactive
oxygen species (ROS) generation and enhanced lipofuscinogenesis
[68]. Interestingly, continuous autophagic intralysosomal degradation
of ferruginousmaterials combinedwith the formation of H2O2 and the
peroxidation of the lysosomal membrane might result in its
subsequent rupture, especially under conditions of oxidative stress,
with release of harmful lysosomal enzymes [69]. If of limited
magnitude, such release can induce ‘reparative autophagy’ [70],
causing additional accumulation of iron and undegradable oxidation
products such as lipofuscin. Finally, these events sensitize cells to
undergo apoptosis as released lysosomal enzymes can attack other
proteins and mitochondria, triggering cytochrome c release with an
ampliﬁcation of the apoptotic program [69].
Taken together, autophagy can have dual roles in the heart (Fig. 2).
Autophagy functions predominantly as a pro-survival pathway duringnutrient deprivation and other forms of cellular stress. However, when
autophagy is severely triggered, the autophagic machinery may also
be used for self-destruction. In this way, autophagic cell death can
occur in cardiac cells and ﬁnally leads to heart failure. Although it is
not known what factors determine whether autophagy will be
protective or detrimental to a cell, it is likely that the level and
duration of autophagy are important [9]. For instance, low levels of
autophagy during ischemia and early reperfusion may protect against
cell death by providing the cell with free fatty acids and amino acids
and by removing damaged organelles, whereas high levels or long-
term upregulation of autophagy during reperfusion can trigger cell
death by excess degradation of essential proteins and organelles. In
addition, there is a complex interrelationship between autophagy and
apoptotic cell death pathways, in which regulators of apoptosis also
function as regulators of autophagic activation [9,71]. One can also
hypothesize that the activation of protective autophagy might be
accompanied by apoptosis. In this situation, depending on the extent
of activation of each of these pathways, some cells would show
traditional autophagic morphology but would survive, some would
show evidence of autophagy but die from apoptosis, while others
would die from apoptosis alone. In situations where apoptosis is
inhibited, e.g. when ATP depletion is extreme, necrosis might occur
[72].
2.7. Therapeutic modulation of autophagy in the heart
Modulation of the autophagic pathway may represent a potential
future therapeutic target to treat or prevent a variety of cardiovascular
diseases. However, despite the discovery of many autophagy-speciﬁc
genes and the dissection of signaling pathways involved in the
regulation of autophagy, therapeutic approaches to modulate autop-
hagy in cardiovascular disease are highly limited. Several possibilities
can explain this discrepancy. First, the few autophagy inhibitors
that are currently used in cell culture experiments, in particular the
class III phosphoinositol kinase (PI3 K) inhibitor 3-methyladenine,
are unsuitable for in vivo applications because of their high toxicity
[73]. Second, the most effective inducer of autophagy in mammalian
cells is nutrient starvation, a strategy which is obviously not attractive
in vivo and even dangerous from a cardiovascular point of view.
Intermittent fasting in rats protects the heart from ischemic injury
and attenuates post-myocardial infarction cardiac remodeling [74],
likely via anti-apoptotic/inﬂammatory mechanisms and possibly via
induction of autophagy, but prolonged starvation triggers severe
cardiovascular complications and cardiac death [75]. Several alter-
native strategies have recently been developed to regulate autophagy
in cardiomyocytes. For example, treatment of UM-X7.1 hamsters, a
model of cardiomyopathy and muscular dystrophy that is caused by
lack of the δ-sarcoglycan gene [76], with granulocyte colony-
stimulating factor signiﬁcantly improves survival, cardiac function
and remodeling in these animals, and such beneﬁcial effects are
accompanied by a reduction in autophagy, an increase in cardiomyo-
cyte size, and a reduction in myocardial ﬁbrosis [77]. Moreover,
autophagy in cardiac myocytes after I/R is also reduced by the
endogenous cardiac peptide urocortin [43] that inhibits beclin 1
expression. Other compounds that are able to regulate autophagy in
the heart include the β-blocker propranolol, the calcium channel
blocker verapamil (both have a stimulatory effect) and the β-
adrenoreceptor agonist isoproterenol that increases cAMP levels
(and inhibits autophagy) [66,78]. These effects are in accordance
with a recently identiﬁed mTOR-independent pathway involving
cAMP–Ca2+–calpains–Gsα, which leads to induction of autophagy
after pharmacological inhibition [79]. Because verapamil, in contrast
to propranolol, affects neither the β-adrenoreceptors nor the
intracellular levels of the second messenger cAMP, it has been
suggested that stimulation of autophagy is a regulatory step in the
adaptation of the heart to a reduction in cardiac output [78]. The
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to treat the heart, as it confers preconditioning-like protection against
I/R injury in isolated mouse heart through opening of mitochondrial
KATP channels [80]. In addition, rapamycin in low doses (25–100 nM)
reduces necrosis as well as apoptosis following simulated ischemia-
reoxygenation in adult cardiomyocytes [80], although the direct
impact of autophagy in these processes is unclear. As explained
above, it is likely that autophagy should be stimulated in the middle of
ischemia but must be inhibited during reperfusion in patients (Fig. 1).
Clinical heart failure results from the cumulative loss of function-
ing myocardium from any cause. Current therapeutics, such as early
myocardial revascularization after myocardial infarction, are focused
exclusively upon minimizing cardiac myocyte necrosis and may even
contribute to secondary apoptosis and autophagy. Two pro-apoptotic
proteins, in particular Bnip3 and Nix, are transcriptionally upregulated
speciﬁcally in response to myocardial ischemia and pathological
hypertrophy and have been examined as therapeutic targets. In Bnip3
and Nix genetic mouse models, prevention of cardiac myocyte
apoptosis in ischemic and hemodynamically overloaded hearts
salvaged myocardium, minimized late ventricular remodeling, and
enhanced ventricular performance. Cardiomyocyte resuscitation, i.e.
bringing cardiac myocytes that are destined to die back to life by
preventing programmed cell death, shows promise as an additional
approach to minimizing cell death for long-term prevention of heart
failure [81].
2.8. Future directions for the study of autophagy in heart disease
The most fundamental question for autophagy in heart disease is
whether its role is harmful or protective. Accumulation of protein
aggregates in cardiomyocytes occurs in response to either hemody-
namic stress or genetic mutation of critical proteins, but experi-
mental evidence shows that autophagy is maladaptive in one
context and beneﬁcial in the other. It is not known whether there
are inherent differences in the types of protein aggregates that form
and/or the associated autophagic response. Some evidence suggests
that increased autophagic activity does not directly clear aggregates
themselves but rather clears aggregate precursors, shifting the
equilibrium away from aggregate formation [82]. The pathophysio-
logical outcome may be determined by severity and/or duration of
the autophagic response or the nature of the autophagic substrate.
This dose- and context-dependent role of autophagy in heart
disease poses special challenges [83]. At present, it is not known
how long one can activate autophagy without detrimental con-
sequences for the cell. Moreover, there is no good explanation for
the discrepancy between the fact that autophagic cell death in
cardiomyocytes of patients suffering from heart failure is only
observed in a minority of cells, while the functional impact is often
dramatic. In addition, we do not know whether senescent SMCs or
long-living cells such as cardiomyocytes are less capable of inducing
autophagy as compared to other cell types. From a therapeutic point
of view, the challenge for clinicians will be to selectively turn on
autophagy-mediated survival in the treatment of heart disease
without activating death pathways.
3. Autophagy in atherosclerosis
Atherosclerosis is a chronic inﬂammatory disease of arteries and
leads to the development of plaques in the vessel wall. Recent
evidence indicates that not only the size but also the stability of the
plaque has major clinical implications. When a plaque develops an
unstable phenotype, it may easily rupture followed by thrombosis,
myocardial infarction or sudden death. Such plaques have a relatively
large lipid core, high macrophage content and a thin ﬁbrous cap. It is
well known that macrophages in the plaque initiate SMC death via
Fas/Fas-L interactions and the production of cytotoxic compounds.Moreover, secretion of metalloproteinases by macrophages results in
degradation of collagen and thinning of the ﬁbrous cap. As a
consequence, it is generally assumed that macrophages play a key
role in plaque destabilization and rupture, while SMCs contribute to
plaque stability [84]. The role of autophagy in atherosclerosis is still
poorly understood. Due to technical and practical limitations for
detection [85] but also due to the lack of adequate marker proteins,
the occurrence of this process in atherosclerotic plaques has not yet
been analyzed in detail [86].
3.1. Basal autophagy is a survival mechanism in atherosclerotic plaques
and is anti-apoptotic
Disintegrating SMCs in the ﬁbrous cap of experimental or human
plaques show certain features of autophagy using transmission
electron microscopy, such as severe vacuolization and formation of
myelin ﬁgures, which are phospholipids and membrane fragments,
often arranged in concentric rings, representing autophagic degrada-
tion of membranous cellular components. These structures are not
abundantly present in human atherosclerosis, but they can be
detected in plaques from cholesterol-fed rabbits [87] as well as after
treatment of cultured SMCs with oxidized lipids [88]. Since autophagy
is often considered as a survival mechanism and not as a death
pathway [89], it is likely that autophagy of SMCs in the ﬁbrous cap of
advanced plaques is in the ﬁrst place an important mechanism for
plaque stability. Indeed, SMCs can produce collagen ﬁbers which
contribute to the tensile strength of the ﬁbrous cap. Moreover,
autophagy can protect plaque cells against oxidative stress by
degrading the damaged material, in particular polarized mitochondria
in the very early stages before cytochrome c release occurs [90]. In this
way, successful autophagy of the damaged components is anti-
apoptotic and contributes to cellular recovery (Fig. 2). However, acute
or persistent oxidative stress results in an intracellular increase of ROS
that damage the lysosomal membrane [90]. Alteration of the
lysosomal compartment prevents fusion with autophagic vacuoles
containing damaged components, and results in the release of potent
hydrolases, enhancing the degree of cellular damage. If autophagy is
not engaged as part of the oxidative stress response in atherosclerotic
plaques, or when oxidative injury overcomes the cellular defenses,
cells probably die via apoptosis [90] (Fig. 2). The protective role of
autophagy in atherosclerosis is also illustrated by the ﬁnding that SMC
death induced by low concentrations of statins is not stimulated, but
attenuated by the autophagy inducer 7-ketocholesterol [91]. Possibly,
the engulfment of defective mitochondria by autophagosomes limits
the release of pro-apoptotic proteins, such as cytochrome c and
apoptosis inducing factor, into the cytosol [92].
Beside its important anti-apoptotic role in atherosclerotic
plaques, autophagy may also downregulate apolipoprotein-B (apoB)-
containing lipoproteins in the circulation. Retention of apoB-containing
lipoproteins within the arterial wall is an important initiating event in
the pathogenesis of atherosclerosis. Dietary polyunsaturated fatty
acids induce the appearance of intracellular aggregates of apoB in the
liver [93,94]. These aggregates slowly degrade by an autophagic
process, thereby inhibiting the export of apoB-lipoproteins by hepa-
tocytes and the subsequent inﬁltration of these compounds in the
vessel wall.
3.2. Ceroid that is formed via autophagy in atherosclerotic arteries
impairs autophagy and induces apoptosis
Apart from its protective role, autophagy in atherosclerosis is
responsible for the formation of ceroid, which is an insoluble
complex of protein associated with oxidized lipids found in all
human atherosclerotic lesions [95]. The process of ceroid formation
is similar to lipofuscinogenesis (see above) and involves severe
oxidative stress combined with autophagy. Iron and ceroid deposits
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macrophages or SMCs of advanced plaques [96]. Ceroid deposits
cannot be degraded by lysosomal hydrolases and might lead to
preferential allocation of the lysosomal enzymes to ceroid-loaded
lysosomes at the expense of active autolysosomes which in turn
would lead to progressive impairment of autophagy and the
induction of apoptosis [69] (Fig. 2).
3.3. Excessively stimulated autophagy may cause autophagic death in
plaque cells
In contrast to basal autophagy, excessively stimulated autophagy
may cause autophagic SMC death [89], which in turn results in plaque
destabilization owing to the reduced synthesis of collagen and
thinning of the ﬁbrous cap. Also autophagic death of endothelial
cells may be detrimental for the structure of the plaque as endothelial
injury and/or death represents a primarymechanism for acute clinical
events by promoting lesional thrombosis (Fig. 2). In vitro observations
suggest that various atherosclerosis-related factors stimulate autop-
hagy in plaque cells as discussed below.
3.4. Autophagy is stimulated by oxidized lipids and removes harmful
oxidatively modiﬁed proteins in atherosclerotic plaques
During atherosclerotic plaque formation, low-density lipoproteins
(LDL) inﬁltrate atherosclerosis-prone arterial regions where they are
oxidatively or enzymatically modiﬁed. Oxidative degradation of
inﬁltrated lipids generates several bioactive intermediates and end-
products [97], including lipid hydroperoxides and lipid peroxidation-
derived aldehydes such as malondialdehyde or 4-hydroxynonenal (4-
HNE). Exposure of SMCs to 4-HNE leads to the modiﬁcation of several
proteins and evokes autophagosome formation [98]. Protein mod-
iﬁcations by 4-HNE may be harmful not only because they disrupt
protein function but also because they lead to the accumulation of
inactive or cross-linked proteins, which must be removed to prevent
further toxicity. Proteasome-mediated degradation is of minor
importance for the removal of these modiﬁed proteins [99]. However,
protein-aldehyde adducts may be degraded as part of the autophagic
response. Indeed, inhibition of autophagy increases the accumulation
of protein-4-HNE adducts, whereas the removal of protein-4-HNE
adducts is enhanced by the autophagy stimulator rapamycin [98]. 4-
HNE treated cells display several characteristics of autophagy, yet the
mechanisms by which 4-HNE or protein-4-HNE adducts trigger
autophagy are not completely understood. Because oxidative stress
is a well-known stimulus of autophagy to facilitate the removal of
damaged organelles [90], autophagy may be induced by increased
generation of ROS and oxidative injury (Fig. 2). Products of lipid
peroxidation could also directly trigger autophagic signaling through
formation of electrophile-modiﬁed or cross-linked proteins. Autop-
hagy can also be evoked by oxidized LDL (oxLDL) [100]. One of the
major oxysterols present in oxLDL, 7-ketocholesterol, not only triggers
protein-4-HNE modiﬁcation and oxidative damage, but also induces
signs of autophagy in SMCs [88].
3.5. Autophagy is stimulated by inﬂammation and removes damaged
components in atherosclerotic plaques
Together with monocytes, T-lymphocytes inﬁltrate the arterial
intima at an early stage in atherogenesis and release pro-inﬂammatory
cytokines such as IFN-γ, interleukin (IL)-2 and TNFα [101]. It has been
shown that these cytokines stimulate autophagy [102–104]. Given the
predominantly pro-inﬂammatory Th1 type immune response in
atherosclerosis [101], inﬂammatory cells in advanced plaques serve
as an important source of pro-autophagic stimuli. Th2 cytokines IL-4
and IL-13 have the potential to act as suppressors of autophagy because
they stimulate type I PI3 K and thus also mTOR [102].In macrophage-derived foam cells, inducible nitric oxide synthase
is upregulated leading to the production of cytotoxic amounts of NO
[105]. NO may contribute to oxidative stress and tissue damage
through formation of peroxynitrite, which can potentially oxidize
and/or damage polyunsaturated fatty acids, sulfhydryl groups and
cellular DNA. This process may evoke an autophagic response to
remove the damaged material [90].
3.6. Hypoxia and metabolic stress in atherosclerotic plaques stimulate
autophagy to protect cells against severe cellular damage
In advanced human atherosclerotic plaques, inadequate vascular-
ization causes hypoxia and hypoxia-induced cell death [106]. Nutrient
starvation induces autophagy [107], whereas metabolic stress (nutri-
ent deprivation combined with hypoxia) leads to damage to
organelles, proteins, and DNA that potently stimulates apoptosis
[108]. As autophagy is not only an alternate means to generate ATP
during starvation, but alsomaintains homeostasis through protein and
organelle quality control, autophagy can mitigate metabolic stress to
protect cells against severe cellular damage [109] (Fig. 2). Furthermore,
SMCs in the ﬁbrous cap of advanced humanplaques are surrounded by
a thick layer of basal lamina [110]. Therefore, it is conceivable that
autophagy in these caged cells is stimulated as a result of starvation.
3.7. Therapeutic modulation of autophagy in atherosclerosis
Because macrophages play a central role in atherosclerotic plaque
destabilization [111], selective inductionofmacrophagedeathnowgains
increasing attention in cardiovascular medicine to stabilize vulnerable,
rupture-prone lesions [112]. Compared with apoptosis or necrosis,
autophagy seems to be an interesting type of death to eliminate
macrophages in atherosclerotic plaques, at least froma theoretical point
of view, because autophagic cells literally digest themselves to death. As
a consequence, the cytoplasmic content progressively decreases so that
activation of inﬂammatory responses, the release of matrix degrading
proteases and the deposition of necrotic debris after postautophagic
necrosis is minimal. However, sometimes strategies to clear macro-
phages in plaques can be hampered by lack of speciﬁcity or unexpected
adverse effects. For example, the pancaspase inhibitor z-VAD-fmk
induces autophagy and necrotic cell death in J774A.1 and RAW264.7
macrophages as well as in IFN-γ primed primary mouse peritoneal
macrophages, but not in vascular SMCs or C2C12 myoblasts [113].
Presumably, autophagy acts as a cell survival mechanism to protect
against z-VAD-fmk-induced necrotic cell death [114]. z-VAD-fmk-
treated J774A.1 macrophages overexpress and secrete several chemo-
kines and cytokines, including TNFα [113]. The combination of z-VAD-
fmk and TNFα, but not TNFα alone, induces SMC necrosis [113]. In this
regard, z-VAD-fmk is detrimental and not beneﬁcial for atherosclerotic
plaque stability due to the stimulation of an inﬂammatory response and
indirect induction of SMC death.
3.7.1. Selective depletion of macrophages in atherosclerotic plaques via
autophagy induction through inhibition of mTOR-dependent pathways
Inhibition of mTOR by rapamycin or its derivatives (rapalogs)
mimics amino acid and growth factor deprivation, and exerts a
cytostatic effect on proliferating cells [115]. By blocking proliferation of
activated Tcells, rapamycin is used as an immunosuppressant in organ
transplantation. Its ability to inhibit SMC proliferation andmigration is
the pharmacological base of its use as a therapeutic agent to prevent
restenosis after balloon angioplasty and stenting [115]. In addition to
its effects on cell growth, inhibition of mTOR may lead to autophagic
cell death through activation and/or upregulation of certain Atg
proteins [116]. For example, Atg13 is rapidly dephosphorylated upon
inhibition of the mTOR pathway, stimulating its afﬁnity for Atg1. The
Atg1–Atg13 association is required for autophagosome formation
[117]. Stent-based delivery of the rapamycin derivative everolimus in
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macrophages through autophagic cell death induction without
altering the SMC content [118]. Everolimus inhibits de novo protein
synthesis in both macrophages and SMCs by dephosphorylating the
downstreammTOR target p70 S6 kinase, followed by bulk degradation
of long-lived proteins, processing of microtubule-associated protein
light-chain 3 (LC3) and cytoplasmic vacuolization in macrophages but
not in SMCs [118]. Interestingly, apart from the mTOR pathway, local
administration of the protein synthesis inhibitor cycloheximide also
induces selective macrophage death in rabbit atherosclerotic plaques,
but in contrast to everolimus, apoptosis and not autophagy is induced
[119]. The mechanism for the selective induction of autophagic cell
death in macrophages versus SMCs is not completely understood.
However, measurements of oxygen consumption [120] as well as
immunodetection of markers for DNA synthesis/repair [121] indicate
that plaque macrophages are metabolically highly active and conse-
quently more sensitive to protein synthesis inhibitors as compared to
SMCs. Moreover, inhibition of translation in SMCs by rapamycin
induces a modulation towards a differentiated, quiescent, contractile
phenotype, whichmay render SMCs relatively insensitive to cell death
mediated by inhibition of protein translation [122]. Therefore,
inhibition of translation rather than differential expression of cell
death proteins seems to be the major trigger that drives selective
induction of macrophage death.
3.7.2. Selective depletion of macrophages in atherosclerotic plaques via
autophagy induction through modulation of mTOR-independent
pathways
Autophagy can also be induced in atherosclerotic plaques through
modulation of mTOR-independent pathways. For example, lithium,
which is an inhibitor of inositol monophosphatase, depletes free
inositol and reduces the levels of 1,4,5-inositol triphosphate [123].
Recent experiments in our laboratory showed that treatment with
lithium triggers selectivemacrophage death (I. DeMeyer, unpublished
data, 2008). Furthermore, the imidazoquinoline compound imiqui-
mod stimulates autophagy after binding to Toll-like receptor 7 (TLR7)
[124]. This protein is expressed only in immune cells so that
imiquimod is able to induce autophagic death in macrophages, but
not in SMCs (I. De Meyer, unpublished data, 2008). However, a clear
link between the downstream signaling pathways induced by TLR7
and autophagy cannot be drawn at present. Recently, another mTOR-
independent autophagy pathway involving cAMP–Ca2+–calpains–
Gsα has been described [79]. Pharmacological inhibition of this
pathway induces autophagy. This can be achieved by e.g. the L-type
Ca2+ channel blocker verapamil. Whether this pathway affects
macrophages or other cell types in the plaque is presently unknown.
Furthermore, small molecule enhancers of rapamycin (SMERs) have
recently been identiﬁed [125]. Three SMERs induce autophagy
independently, or downstream of mTOR. In combination with
rapamycin at concentrations saturating for its pro-autophagic activity,
these SMERs result in greater rates of autophagy substrate clearance,
compared to either the SMERs or rapamycin alone.
Dietary or pharmacological lipid lowering is a well-known
approach to clear macrophages in atherosclerotic plaques [126,127].
However, loss of macrophages in rabbit atherosclerotic plaques after
lipid lowering seems not to be related to induction of macrophage
apoptosis, but is mainly a consequence of impaired monocyte
recruitment followed by decreased macrophage replication. Alterna-
tively, monocyte-derived cells can emigrate from the plaque [128]
during lesion regression, and depletion of cholesterol may induce
autophagy [129], possibly due to disruption of cholesterol-rich lipid
rafts. The resultant downregulation of Akt activity [130,131] leads to
suppression of mTOR and autophagy induction. However, only drastic
cholesterol depletionmethods induce autophagy of cells in vitro [129].
Because LDL-levels of cholesterol-fed rabbits do not dramatically
change during the ﬁrst weeks of dietary lipid lowering, we feel that, atleast in the ﬁrst weeks, induction of autophagy is not involved in
macrophage clearance after cholesterol withdrawal.
Both cholesterol and plant sterols are present in our diet, but
intestinal epithelial cells selectively and efﬁciently rid the body of
plant sterols. However, a raremutation in plant sterol excretion results
in the accumulation of plant sterols in plasma and tissues, leading to
sitosterolemia. The excess atherosclerotic heart disease in patients
with sitosterolemia may be explained by the observation that excess
cholesterol kills macrophages by caspase-dependent apoptosis,
whereas sitosterol-induced macrophage death occurs by autophagy
and necroptosis [132].
3.8. Future directions for the study of autophagy in atherosclerosis
Crossbreeding of mouse models for atherosclerosis (e.g. ApoE or
LDL receptor knockout animals) with autophagy deﬁcient mice (e.g.
conditional Atg5 knockout animals) might give further insight
whether autophagy is harmful or protective in atherosclerotic
plaques. Most likely, autophagy under basal conditions plays an
important role in cellular housekeeping, while induced autophagy
may function as a death pathway.
Stimulation of survival via autophagy in SMCs of vulnerable
atherosclerotic plaques can help to prevent coronary artery syndromes
and sudden death. Furthermore, selective clearance of macrophages in
atherosclerotic plaques via drug-induced autophagy is a promising
approach, but probably only a ﬁrst step toward plaque stabilization. A
combined approach, e.g. together with dietary lipid lowering or statin
treatment,may be needed to prevent re-inﬁltration ofmacrophages. In
this way long-term plaque stabilizing effects might be obtained.
Although pharmacological induction of autophagic cell death in
macrophages is believed to be the preferred type of death to deplete
this type of cells from atherosclerotic plaques [133], it should be noted
that also this approach might involve certain adverse effects. In vitro,
autophagicmacrophages produce pro-inﬂammatory cytokines such as
TNFα and IL-6 [134], suggesting that the autophagic process is not
immunologically silent. Moreover, it remains unclear what happens
with the large amount of oxidized lipids in the cytoplasm of
macrophage-derived foam cells undergoing autophagy. It is tempting
to speculate that lipids in the cytosol are not adequately digested
during autophagy owing to overload or exhaustion of lysosomal
enzymes. Furthermore, an increase rather than a decrease in foam cell
formation can be expected in macrophages undergoing autophagy
because protein degradation as well as the decline of protein synthesis
in autophagic cells readily blocks the utilization of lipids for lipid–
protein conjugation which in turn results in the formation of lipid
droplets [133]. These lipid droplets can be spilled out in the micro-
environment of the plaquewhen the autophagic cell collapses, thereby
attracting new mononuclear cells from the circulation. Further
research is needed before autophagic death of macrophages can be
exploited to therapeutic advantage in unstable atherosclerotic plaques.
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